South Korea’s clinical-stage biotech D&D Pharmatech (Kosdaq: 347850) saw its share leap as much as 30% as it revealed “remarkably positive” results on its metabolic dysfunction-associated steatohepatitis (MASH) candidate.
The company announced positive results from DD01-DN-02 study, an ongoing 48-week Phase II trial designed to evaluate the efficacy and safety of DD01 (a once-weekly dual GLP1/glucagon receptor agonist) in 67 overweight/obese subjects with MASH.
DD01 treatment was initiated with two weeks of dosing at 20mg, followed by the 40mg once-weekly maintenance dose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze